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The mitochondrion is the major energy generating organelle of the cell and the site of other basic processes, including apoptosis. The
mitochondrial functions are performed in concert with other cell compartments and are regulated by various extracellular and intracellular signals.
Several nuclear receptors and other nuclear transcription factors, such as NF-κB, AP-1, CREB and p53, involved in growth, metabolic and
developmental processes, have been detected in mitochondria. This finding raises the question as to the role of these regulatory molecules in their
“new” environment. Experimental evidence supports the action of the mitochondrially localized transcription factors on mitochondrial transcription,
energy yield and apoptosis, extending the known nuclear role of these molecules outside the nucleus. A principle of coordination of nuclear and
mitochondrial gene transcription has been ascertained as regards the regulatory action of steroid and thyroid hormones on energy yield. Accordingly,
the same nuclear receptors, localized in the two compartments–nuclei and mitochondria–regulate transcription of genes serving a common function
by way of interaction with common binding sites in the two genomes. This principle is now expanding to encompass other nuclearly and
mitochondrially localized transcription factors.
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The molecular mechanisms of action and the role of nuclear
transcription factors in their functional environment, the cell
nucleus, have been intensively studied and partially revealed.
This holds true in particular for steroid and thyroid hormone
receptors, a major class of the superfamily of nuclear receptors,
representing ligand activated transcription factors, involved in
the regulation of metabolic, growth, developmental and immune
processes [1]. In the ligand unbound, non-activated state, these
receptors are components of a macromolecular complex with
heat shock and other proteins. Upon binding with the cognate
ligand, the receptors are released from the complex, form dimers
and interact with hormone responsive elements (HREs) in the
regulatory sites of the hormone modulated genes. This initiates⁎ Corresponding author. Tel.: +30 210 7273767; fax: +30 210 7273677.
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doi:10.1016/j.bbamcr.2007.10.021a series of events involving several interacting proteins, e.g.
transcription factors, coactivators and corepressors, histone
modifying enzymes and the basal transcription machinery,
leading to chromatin restructuring, culminating in the activation
or repression of gene transcription [2]. In the case of action of
thyroid hormones, the cognate receptor is found bound to
chromatin, acting as a transcription repressor, from which it is
released after interaction with the hormone, leading thus to
transcription activation. Regulation of transcription can also be
attained by interaction of the receptors as monomers, not directly
with DNA, but with other transcription factors having direct
access to respective DNA binding sequences [3]. Furthermore,
hormones exert rapid, non-genomic effects [4] by way of
classical receptors, G-protein associated receptors, or other still
unidentified molecules [5,6] (Fig. 1). A host of other nuclear
transcription factors has been characterized, e.g. NF-κΒ, ΑΡ-1,
CREB and p53, activated by extracellular or intracellular
regulatory molecules, involved in cell growth, differentiation,
Fig. 1. Mechanisms of action of steroid hormones in the example of glucocorticoids. The steroid hormones, by way of binding to cognate receptors and interaction with
Hormone Responsive Elements, can (a) activate or (b) attenuate gene transcription. By protein–protein interaction of the hormone—receptor complex with other
transcription factors the hormone can (c) activate, or (d) block gene transcription. The hormone can also lead to rapid, non-genomic effects (e) by way of classical
receptor forms, G-protein coupled receptors or still unidentified molecules and signal transduction mechanisms. In mitochondria (f), the hormone—receptor complex,
by interaction with the mitochondrial genome, can modulate mitochondrial transcription. GR, Glucocorticoid receptor; NF-κB, Nuclear Factor κB; AP-1, Activator
Protein-1; STAT5, signal transducer and activator of transcription 5 [adapted from 5].
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nuclear receptors and the other transcription factors exert their
physiological functions was centered mainly on their action
within the nuclear environment and their interaction with nuclear
genes. The detection of steroid and thyroid hormone receptors in
mitochondria of various cells and tissues raised the question of
their role in this “new” environment, in particular their possible
involvement in the regulation of mitochondrial transcription
[5,7–11].
2. Nuclear receptors in mitochondria: Role in mitochondrial
transcription and coordination of expression of genes encoding
enzymes of oxidative phosphorylation (OXPHOS)
Receptors for glucocorticoids [12–18], estrogens [11,19–28],
androgens [26], thyroid hormones [5,29–32], the retinoid
receptor alpha (RXRα) [31,33], the retinoic acid receptor
(RAR) [34], the orphan receptor Nur77/TR3 [35,36] and the
peroxisome proliferator-activated receptor β- and γ2-coactivator
(PPAR β- and γ2) related proteins [37], have been found in
mitochondria of lymphocytes, of rat liver, brain,Mueller glia cells
and periodontal ligament, of spermatocytes and of many cell lines
[5,38].
Mitochondria are vital organelles, participating in important
cellular functions [39]. They providemore than 90%of the energy
requirements of the cell by way of oxidative phosphorylation in
the respiratory chain (Fig. 2). Mitochondria are involved in many
steps of intermediary metabolism, in urea production, hemebiosynthesis and β-oxidation of fatty acids. Furthermore,
mitochondria are key components of the stress response [46],
they play a central role in oxidative stress by way of reactive
oxygen species (ROS) generation [27], in immunomodulation
[47,48], in cell differentiation [49] and in ageing [50]. Derange-
ments of mitochondrial functions have been etiologically
correlated to neuromuscular degenerative diseases [51,52], such
as Alzheimer's disease, Parkinson's disease, amyotrophic lateral
sclerosis, and in cancer [53–55] (Fig. 2).
This central role of mitochondria in cell metabolism,
necessitates an integration and coordination of their functions
with those of other cell organelles, importantly with the cell
nucleus [5,13,48,56–62]. Energy production by way of
oxidative phosphorylation is such a function, in which both
nuclear and mitochondrially encoded enzymes of oxidative
phosphorylation (OXPHOS) are needed for the formation of
active respiratory complexes [63]. Themitochondrion is a sensor
of the energy requirements of the cell [64] attaining various
levels of adaptive regulation of OXPHOS [57,64]. If the energy
needs are not excessive, the respiratory chain increases the ATP
yield by allosteric activation of the OXPHOS by metabolites,
such as ADP. In cases of higher energy needs, such as evoked by
glucocorticoid and thyroid hormones in target cells and during
certain developmental periods [65,66], the cells react by in-
creased biosynthesis of OXPHOS or, in extreme cases, by mi-
tochondrial biogenesis, implicating increased transcription of
nuclear and mitochondrial OXPHOS genes and increase in gene
dosage [67].
Fig. 2. The mammalian mitochondrial genome [40] and sites on the genome of
sequences showing similarity to hormone responsive elements (HREs) for
steroid and thyroid hormones. The mammalian mitochondrial genome is a
circular double-stranded molecule of approximately 16 Kb (human: 16,569
bases). The two strands of the DNA have an asymmetric distribution of purines
and pyrimidines, generating heavy (H) and light (L) strands. The L strand is
transcribed from one predominant promoter (PL), whereas the H strand is
transcribed from two adjacent promoters (PH1 and PH2), located in the control
region which includes a displacement (D) loop. The absence of intragenic space
denotes that modulation of gene expression is confined to the D-loop, although
the possible presence of intragenic regulatory sequences could offer possibilities
of regulation of other stages of the transcription process. Transcription ema-
nating from PH2 and PL generates long, polycistronic products, some of which
are nearly full-genome length, subsequently processed at the sites of transfer
RNA coding genes, liberating mature mRNAs and tRNAs. Transcription from
PH1 produces a short message containing the two rRNAs, terminating at a
specific site on the tRNA-Leu gene. A transcription terminating factor (mTERF)
promotes the termination of transcription initiated at the PH1 site. The mRNAs
encode three subunits of cytochrome oxidase (I, II and III, COX I, COX II, COX
III), seven of NADH-CoQ-reductase (ND 1–6 and ND4L), one of cytochrome b
(cyt-b), two of ATP-synthase (ATP 6, 8), two ribosomal RNAs (12S and 16S
rRNA) and 22 tRNAs. Only ND6 and the Gln, Ala, Asn, Cys, Tyr, Ser, Glu and
Pro-tRNAs are generated from the light strand transcript. Three transcription
factors have been characterized, mTFA, mTFB1 and mTFB2. The sites on the
genome of the predicted [8,41] and experimentally verified [9,11,31,42,43]
binding sites for steroid and thyroid hormones are depicted: Open arrows: HREs
for class I receptors, Filled arrows: HREs for class II receptors [adapted from 5].
Several neurodegenerative diseases, e.g. Alzheimer's disease, Parkinson's
disease and Huntington's chorea, appear to be etiologically correlated with
mitochondrial DNA defects. In addition to mutations in the structural genes,
with their known consequences on mitochondrial function, the role of defects in
the mitochondrial genome regulatory sites should be considered in this respect.
This has been previously stressed [5,13,40,44] and indeed experimentally
demonstrated in the case of Alzheimer's disease, where mutations in the D-loop
of brain mitochondria suppressed mitochondrial transcription and replication
[45].
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cell compartments by the hormones emanates from the nucleus,
where the hormone—receptor complex interacts with respective
HREs to induce transcription of nuclear OXPHOS genes and
also of transcription factors for these genes [58,68–70] (Fig. 3).
In addition, mitochondrial transcription factors are induced[56,70,77] which, translocate to the mitochondria. They thus
achieve the required coordination of OXPHOS' gene transcrip-
tion in the two cellular compartments [70]. The presence of
steroid/thyroid hormone receptors in mitochondria and of HRE-
like sequences in the mitochondrial genome [7,9,11,32,41–43]
(Fig. 2) suggested an additional mode of coordination, by way of
a direct effect of the mitochondrially localized receptor on
mitochondrial transcription [5,7,9,11,13,33,61]. Accordingly,
common transcription factors, the receptors, present in the
nucleus and in the mitochondrion, activated by the same regu-
latory agent, the hormone, will ensure the coordination of a
process requiring the parallel transcription of genes residing in
the two cell organelles (Fig. 3).
Several studies in various systems supported an effect of
nuclear receptors on mitochondrial transcription [5,11,65,55].
Direct experimental proof for the action of thyroid hormones on
mitochondrial transcription was provided by the groups of
Enriquez et al. [10] and Casas et al. [78] applying an organello
mitochondrial system capable of sustaining faithful transcription
for several hours [79]. The conclusion from these experiments
was that the regulatory effect of T3 on mitochondrial transcrip-
tion is exerted by a direct influence of the hormone on the
mitochondrial transcription machinery, that it does not require
the previous activation of nuclear genes, and that transcription
initiation was the step affected by T3.
3. Nuclear receptors in mitochondria: Role in apoptosis
The unique role of mitochondria in supplying ATP to the cell
by oxygen metabolism in the respiratory chain, a beneficial step
in the evolutionary organismic explosion, leads invariably to the
generation of reactive oxygen species (ROS), which represent
major intrinsic apoptotic agents. Thus, the fluctuation of energy
production by way of the respiratory chain can, in extreme
cases, have deleterious consequences on cell viability [80,81].
Mitochondria receive and integrate several other intracellular
and extracellular pro- and anti-apoptotic signals, therefore
playing a decisive role in the cell's fate [35,62,82,83].
Steroid hormones are such major regulatory signals of
apoptosis, inducing or inhibiting the process depending on the
nature of the target cells and their mitochondria. These or-
ganelles demonstrate tissue specificity, as underlined by the fact
that only a subset of their proteins are common in mitochondria
of different cell types [84].
Estrogens are important anti-apoptotic signals for many cell
types, such as breast cancer cells, endothelia and brain cells
[25,85–87], whereas glucocorticoids are major apoptotic agents
for thymocytes and leukemic cells [83,88]. A direct involve-
ment of mitochondrial receptors in the apoptotic process in both
cases is now emerging.
Estrogens promote the development, proliferation, migration
and survival of breast cancer cells. The actions of estrogens are
mediated by the two estrogen receptor forms, estrogen receptor
alpha (ERα) and estrogen receptor beta (ERβ). Studies in human
hepatoma derived HepG2 and in human breast tumor MCF-7
cells, have demonstrated that 17β-estradiol administration leads
to translocation of the two estrogen receptors into mitochondria
Fig. 3. Nuclear-cytoplasmic coordination of transcription of mitochondrial and nuclear genes encoding OXPHOS subunits by steroid/thyroid hormones. In the nucleus,
the hormone—receptor complex (NR) can interact with hormone responsive elements (HREs) of oxidative phosphorylation (OXPHOS) genes, to directly activate
them, and with HREs of nuclear respiratory factor (NRF) genes, to induce the respective transcription factors, which can then exert a positive effect on transcription of
nuclear OXPHOS genes. By way of non-genomic modulation of intracellular Ca2+ concentration and activation of the calcium-calmodulin-dependent protein kinase
IV (CaMKIV), the “master regulator” of mitogenesis, peroxisome proliferator-activated receptor γ-coactivator (PGC-1α) [71] is induced, which can directly and
indirectly (be way of NRF induction) stimulate the transcription of nuclear OXPHOS genes and of the mitochondrial transcription factor A (mtTFA), which in
mitochondria activates transcription. PGC-1α and PPARα can also be induced by thyroid hormones [72] and by glucocorticoids [73]. PCG1α/1β can also be induced
by IFNγ by way of the JAK/STAT-1 pathway [74]. PCG1α/1β subsequently can activate the estrogen-related receptor α (ERRα), an orphan nuclear receptor [75],
which by direct binding to promoters of genes important for mitochondrial functions, such as for oxidative phosphorylation or to promoters of factors controlling
mitochondrial expression, lead to increased mitochondrial respiration and ROS production. In mitochondria, the hormones can directly affect transcription of the
OXPHOS genes by way of cognate mitochondrial receptors and interaction with respective binding sites on the mitochondrial genome, ensuring an optimal
coordination of OXPHOS gene transcription in the two genomes. The specific sequences Mt3 and Mt4, present in the 5′-flanking region of the genes encoding the
cytochrome bcl complex and in the D-loop [76] are likely binding sites for still unknown coordinating regulatory factor(s). NRF, nuclear respiratoy factors 1,2; MEF2,
Myocyte enhancer factor 2; ATF2, activating transcription factor 2; CREB, cAMP-response element-binding protein transcription factor; p53, tumor suppressive
protein; NF-κB, Nuclear Factor κB; AP-1, Activator Protein 1 [adapted from 73].
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tochondrial encoded mRNAs for cytochrome oxidase subunits
I, II, and III, and of respiratory enzyme activities [11,89,90]. As
already mentioned, mitochondrial DNA contains sequences
similar to nuclear Estrogen Response Elements (EREs), EMSA
and surface plasmon resonance studies have demonstrated that
the estrogen receptors bind to these sequences [11,89,90].
Therefore, the role of the mitochondrial estrogen receptors in
mitochondrial transcription was considered in the protective
effects of estrogens on apoptosis [90].
Experiments by Hsieh et al. [91,92] support the anti-apoptotic
effect of the mitochondrial ERβ in the case of heart muscle of rats
subjected to trauma and hemorrhage. Under such conditions,
prolonged depression of cardiovascular functions, such as
decreased cardiac output, occurs and the amount of ERβ in
cardiac mitochondria decreases. 17β-estradiol and the ERβ
agonist DPN, but not the agonist of the ERα PPT, restore cardiacfunction and the amount of ERβ inmitochondria.Moreover, 17β-
estradiol increases ERβ binding to mitochondrial DNA. Subse-
quently, the expression of COX I and COX II, the activity of the
respiratory complex IV and the production of ATP increases,
effectswhich underlie the cardioprotective effects of the hormone.
A protective effect of estrogens on cerebral blood vessels and
cultured endothelial cells, also supporting the involvement of
mitochondrial estrogen receptors, has been reported by Stirone et
al. [93], Duckles et al. [27] and Lu et al. [94]. In studies, focused
on the regulation of vascular tone, O'lone et al. [95] applying gene
expression profiling in mouse aorta, observed that ERα and ERβ
regulate distinct and non-overlapping sets of genes. They showed,
that ERβ is essential for most of the estrogen-mediated decrease,
in gene expression. Among the genes attenuated are nuclear genes
encoding subunits of the major respiratory complexes, presum-
ably by direct binding of ERβ to the promoter of these genes. The
downregulation of these genes in the aorta is in contrast to the
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biological consequences of estrogen in the different cell types.
Pedram et al. [25] also focused on the estrogen receptors as
contributing to the mechanisms of cell survival. UV irradiation
of MCF-7 cancer cells increases the mitochondrial generation of
ROS, leading to translocation of the apoptotic factor Bax to
mitochondria, to decrease of the mitochondrial membrane
potential, to release of cytochrome c and finally to apoptosis.
These effects are inhibited by estrogens. To show the direct anti-
apoptotic involvement of the mitochondrial estrogen receptors,
ER-negative breast cancer derived HCC-1569 cells and CHO
cells were transfected with the E-domain (the ligand binding
domain) of the estrogen receptor, specifically targeted either to
the nucleus, or to the mitochondria by linking it with a mito-
chondrial localization signal. Targeting of the E-domain to the
nucleus did not provide estrogen protection of the irradiated
cells. However, the mitochondrially targeted E-domain of the
receptor protected the cells from the UV induced cell death [25].
The applied estrogen receptor construct lacked the DNA binding
domain of the receptor, therefore its anti-apoptotic effect does
not seem to be mediated by a genomic action [25]. Similarly,
estrogen protection from oxidative stress demonstrated by
Razmara et al. [87] was in part due to activating the levels of
manganese superoxide dismutase, the mitochondrial enzyme
which catalyses superoxide radical breakdown. Effects of
estrogens on this enzyme have been previously reported by
Pedram et al. [25].
As regards glucocorticoids, the balance of hormone induced
apoptosis versus apoptosis resistance depends on the cell
lineage. The apoptotic effects of glucocorticoids are well
documented on cells of the hematopoietic system, such as
monocytes, macrophages, thymocytes and leukemic cells and
require the presence of a functional glucocorticoid receptor [96].
In contrast, cells of epithelial origin, such as mammary gland
cells, follicular cells and hepatocytes are protected by gluco-
corticoids against apoptotic stimuli. The bulk of the extensive
work concerning mechanisms of action of these hormones on
apoptosis was centered on their transactivation and transrepres-
sion effects on nuclear apoptotic and anti-apoptotic genes, res-
pectively. Many genes of the extrinsic and intrinsic death
pathways are expressed in a pro-apoptotic manner upon treat-
ment of sensitive lymphoid cells with glucocorticoids [97].
However, these effects alone are insufficient to elicit apoptotic
death and additional signals are required to activate the apoptotic
process.
Work by Sionov et al. [18,97] demonstrated the central role
of the mitochondrial glucocorticoid receptor in the induction of
apoptosis of leukemic cells. Using T-lymphoid cell lines vary-
ing in sensitivity towards glucocorticoids, these authors showed
a rapid glucocorticoid induced translocation of GR in the
mitochondria of sensitive cells, whereas in the resistant cells no
such movement was evident. Furthermore, nuclear targeting of
the receptor after hormone administration was similar in the two
cell lines. Targeting the glucocorticoid receptor to mitochon-
dria, by linking the receptor with the cytochrome oxidase
mitochondrial localization signal, resulted in accumulation of
the receptor in mitochondria and to apoptosis of the cells in aglucocorticoid independent manner. Thymic epithelial cells,
which cause apoptosis of the PDI.6 T-cell line in a gluco-
corticoid receptor dependent manner, induce translocation of
the receptor to the mitochondria, but not to the nucleus, pointing
also to the role of the mitochondrial receptor in eliciting apop-
tosis. These results are similar to the ones obtained by Li et al.
[35], who targeted the nuclear orphan receptor TR3/Nur77
devoid of its DNA binding and transactivation domain to
mitochondria and observed cytochrome c release and apoptosis
and to those of Jeong et al. [36], who induced apoptosis by
synthetic chenodeoxycholic acid derivatives in human cancer
cell lines mediated by TR3/Nurr77 translocation into mitochon-
dria. The experiments of Sionov et al. [18,97] demonstrate that
the exclusive expression of GR in mitochondria is sufficient to
induce apoptosis. The mechanism of action of the translocated
receptor in mitochondria–whether the effects involve non-
genomic or genomic actions or a combination of both–is being
currently explored in the authors' laboratory.
3.1. Other nuclear transcription factor in mitochondria: Role
in mitochondrial transcription and apoptosis
In addition to the nuclear family of receptors, several other
transcription factors with well studied effects on the regulation
of the activity of nuclear genes involved in cell proliferation,
innate immunity and apoptosis, such as NF-κB, AP-1, CREB,
p53, c-Myc [reviewed in 48], Wnt13 [98], Dok-4 [99], HMGA1
[100] and c-Src [101], have been detected in mitochondria
(Fig. 4). Furthermore, binding sites in the mitochondrial
genome for some of these molecules, homologous to their
binding sites in the nuclear genome, have been determined by in
silico methodology [102] and experimentally [103–108]. A role
of these factors in mitochondrial transcription and energy
metabolism in relation to apoptosis is now emerging [61,104–
107,109,110]. In apoptosis, independent of the causative
stimulus, these regulatory molecules in mitochondria mostly
downregulate mitochondrial gene expression, intervening at
various levels of this process.
NF-κB was detected in the intermembrane space of
mitochondria of cells of the human leukemic T-cell line Jurkat,
in association with I-κBα. Upon induction of apoptosis of these
cells by engagement of the Fas surface molecule with a CH11
specific antibody, p65 was released from mitochondria together
with I-κBα [111]. It was suggested, that the reservoir of I-κB and
NF-κB in the intermembrane mitochondrial space could be
involved in modulating apoptosis responses. NF-κB was also
found in mitochondria of human fibroblast HT1080 cell lines,
of human prostate LNCaP and PC3 cell lines [105] and of
HeLa cells [112]. Cogswell et al. [113] reported the
localization of NF-κB and I-κBα in mitochondria of U937
leukemia cells. Stimulation of the cells with TNFα led to
degradation of I-κBα. Importantly, cytokine treatment reduced
the expression of the mitochrondrially encoded cytochrome c
oxidase III and cytochrome bmRNA. Blocking the activation of
mitochondrial NF-κB by expression of the superrepressor form
of I-κBα restored the expression of both cytochrome c oxidase
III and cytochrome bmRNA. These results demonstrate that the
Fig. 4. Nuclear receptors, other transcription factors and regulatory molecules present in mitochondria. GR, Glucocorticoid receptor; ER, Estrogen receptor; AR,
androgen receptor; TR, Thyroid receptor; NR77/TR3, orphan receptor NR77/TR3 [36]; RXR, Retinoid X Receptor; RAR, Retinoic Acid Receptor; PPARα,
Peroxisome Proliferator-Activated Receptor α; NF-κB, Nuclear Factor κB; p53, tumor suppressive protein; CREB, cAMP-response element-binding protein
transcription factor; AP1, Activator Protein 1; c-Myc, c-Myc oncogenes protein; I-κΒ, inhibitor of NF-κΒ; SLIRP, SRA stem–loop interacting RNA binding protein;
Dok-4, downstream of tyrosine kinase adaptor protein 4 [99]; HMGA1, High Mobility Group A1 [100]; c-Src, cellular tyrosine kinase Src [101]; WNT2, Wingless-
type MMTV integration site, family member 2.
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transcription factor negatively regulates mitochondrial mRNA
expression.
The NF-κB p65 and p50 subunits detected in prostate LNCaP
cell mitochondria, were in part bound to mitochondrial DNA
[105]. This binding was increased by treatment of the cells with
the TNF related apoptosis inducing ligand (TRAIL), without
increasing the amount of NF-κB, suggesting activation of the
transcription factor in the absence of additional translocation to
the mitochondria. TRAIL treatment also led to decrease of
mitochondrial encoded cytochrome oxidase III mRNA levels.
The decrease was prevented by inhibiting NF-κB, pointing to the
possible role of mitochondrial NF-κB in regulating mitochon-
drial gene transcription [106].
AP-1 is found in mitochondria of rat cerebral cortex cells and
of dental granular cells [103,104] and its role there is currently
being explored in relation to the action of glutamic acid and its
agonist kainate. These excitatory agents participate in several
neuronal functions by way of interaction with cognate receptors.
In mice, they induce the expression of c-fos and c-jun and
enhance binding of AP-1 to DNA both in nuclear and in mito-
chondrial extracts, as demonstrated by electrophoretic mobility
shift assays (EMSA). This binding could be competed by
oligonucleotides with sequence similarity to the AP-1 binding
sites detected in the non-coding region of the mitochondrial
DNA. The mitochondrial binding site of AP-1 was found to be
localized in the D-loop region of the genome [104]. It was
suggested, that kainate may facilitate the expression of the AP-1
complex and its subsequent translocation into mitochondria,
where it could participate in mechanisms associated with
regulation of mitochondrial DNA transcription. AP-1 has alsobeen detected in mitochondria of prostate LNCaP cancer cells
and binding of the transcription factor to mitochondrial DNA
was demonstrated. TRAIL treatment of the cells for 4 h led to
maximal mitochondrial DNA binding activity of AP-1 and to
decrease of mitochondrially encoded mRNA levels. This also
suggested involvement of AP-1 in mitochondrial transcription in
the TRAIL induced apoptosis of the cancer cells [105].
In studies dealing with the role of CREB in synaptic
transmission, retrograde memory and brain function, this
transcription factor was detected in rat brain mitochondria,
concentrated in the inner membrane [109].Mitochondrial CREB
can be phosphorylated by a mitochondrially localized protein
kinase A and can bind to double-stranded DNA containing the
calcium-cyclic AMP-responsive element consensus sequence,
as demonstrated by EMSA. These findings were confirmed by
Schuh et al. [110]. Furthermore, both a phosphorylated and a
non-phosphorylated form of CREB were found, as well as a
calcium dependent phosphatase which regulates the phosphor-
ylation state of the transcription factor [110]. CREB and protein
kinase Awere also found in the mitochondrial matrix of mouse
neurons [108,109]. CREB-binding sites on the D-loop of the
mitochondrial genome were also identified by CHIP analysis.
Interestingly, dexerozamine, an antioxidant and iron chelator,
known to inhibit oxidative stress-induced death, activated
mitochondrial PKA, increased mitochondrial CREB phosphor-
ylation and CREB binding to cognate responsive elements in the
D-loop of the mitochondrial genome. It was suggested [107],
that mitochondrial gene transcription modulation by CREB
underlies the salutary effects of dexerozamine.
Several publications report the presence of p53 in mitochon-
dria of various cell types (fibroblasts, human HT1080 cells,
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blood mononuclear cells [114–123]. In apoptotic myeloid
leukemia ML-1- and colorectal carcinoma RKO-cells, induced
either by DNA damage or by hypoxia, a small but significant
fraction of the stress-induced p53 was detected in the inner
mitochondrial membrane, but also within the mitochondria,
translocating from the cytoplasm [116]. The translocation of p53
in mitochondria is rapid and precedes the observed effects on
mitochondrial membrane permeabilization and release of cyto-
chrome c. These effects are blocked by overexpression of the anti-
apoptotic protein Bcl-2 and BclX2 due to the formation of
inhibitory complexes of these proteins with p53. Targeting of p53
linked to the mitochondrial leader sequence of ornithine
transcarbamylase to mitochondria of p53-null SaOS-2 osteosar-
coma cells, was sufficient to induce apoptosis in the tumor cells.
Using deletion mutants of p53, the authors showed that the
transactivation activity of p53 is fully dispensable for its
mitochondrial action [116,120], pointing to a non-genomic action
of mitochondrial p53 in apoptosis in this cell system. Similar
findings have been reported in the irradiation induced apoptosis of
mice thymocytes [118], in which also p53 was found in
mitochondria. In irradiated thymocytes, p53 directly induces
permeabilization of the outer mitochondrial membrane by
forming complexes with protective BclXL through its DNA
binding domain, resulting in cytochrome c release. Mutant p53 is
unable to form BclXL complexes and does not lead to release
cytochrome c from the mitochondria. However, a p53 binding
motif within the 16S gene of the mitochondrion was found,
conferring p53 responsiveness to a reporter gene in transfection
experiments [106]. Furthermore, in hydrogen peroxide stressedFig. 5. The dual role of nuclear transcription factors on survival/apoptosis by way of
directly on both the nuclear and the mitochondrial genome in the process of apoptos
AP-1, Activator Protein 1; NF-κB, Nuclear Factor κB; HR, Hormone Receptor; CR
suppressive protein; OXPHOS, oxidative phosphorylation; c-Myc, c-Myc oncogeneHA-1 fibroblasts, a specific downregulation of mitochondrial
RNA encoding OXPHOS, but not of nuclear RNA, was observed
[117], as well as an inhibitory effect of a dominant-negative p53
mutant on the expression of mitochondrial 16S rRNA [121,122].
Also, p53 directly interacts with the mitochondrial transcription
factor mtTFA [123]. These findings support a direct, negative
effect of p53 on mitochondrial transcription in stress-related
apoptotic states, in addition to its non-genomic actions.
3.2. The mitochondrion as a primary receiver and integrator
of regulatory signal acting in cooperation with the nucleus
The recent explosion in the literature as regards the multiple
functions of mitochondria, has exposed the role of these or-
ganelles not only as simple powerhouses and providers of the
cell's energy requirements, but as a key site and important integ-
rator of regulatory signals affecting the cell's fate—division,
growth, differentiation, survival and apoptosis [5,52,57–62].
During the long history of symbiosis of the invading proteo-
bacterium turned mitochondrion with its eukaryotic host [124],
an adaptation of the functions of the new organelle to the regu-
latory mechanisms of the cell was necessary and apparently a
prerequisite for the survival of both symbiont and host. Signi-
ficantly, recent proteome analysis of the mitochondrion [84,125]
has revealed proteins originally derived from the eubacterial
ancestor and proteins that have been acquired from the host
during the last two and a half billion years of symbiosis, some of
which belong to the class of nuclear regulatory proteins.
As already presented, mitochondria host several transcription
factors involved in the regulation of nuclear gene activitynuclear and mitochondrial gene regulation. Nuclear transcription factors acting
is/survival induced by hormones, growth factors, cytokines and oxidative stress.
EB, cAMP-response element-binding protein transcription factor; p53, tumor
s protein.
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survival [reviewed in 5,61], whose role was previously regarded
as solely nuclear. The mitochondrial localization of these trans-
cription factors and the information obtained on their mechanism
of action in mitochondria was instrumental in underlining the
significant role of mitochondria as direct, primary receivers of
regulatory signals, and in revealing their expanded and complex
role in cell physiology (Fig. 5).
Regulation of energy production is one of the critical
processes determining the cell's pathway towards survival and
growth or apoptosis. It requires the participation of several
mitochondrial and nuclear components, and, importantly, the
coordination of the process in these two cell compartments.
Indeed, oxidative phosphorylation, ATP production and its
hormonal control can be viewed from the perspective of signal
integration and coordination of gene activity carried out in
different cell organelles as well as a paradigm of action of
regulatory proteins undertaking a dual–in this case mitochon-
drial and nuclear–but common role. Thus, a hormone, steroid or
thyroid, by way of common nuclear and mitochondrial transa-
cting receptor proteins and common DNA binding sites for
these receptors in the two genomes, can induce the expression
of OXPHOS, providing coordinate transcription regulation.
Apoptosis is another vital cell process in which mitochondria
play a major role. The mitochondria receive and integrate a
series of apoptotic and survival signals, key among them the
steroid hormones, with their demonstrable dual survival/
apoptotic effects. In the apoptotic/anti-apoptotic action of
these hormones in mitochondria, the role of mitochondrial
receptors has been shown to be instrumental. Other nuclear
regulatory proteins detected in mitochondria, such as the
transcription factors NF-κB, AP-1, CREB and p53, have a
well defined role within the nucleus—they participate in the
regulation of genes, among them genes affecting apoptosis.
Some of these transcription factors (NF-κB, AP-I and CREB)
induce the expression of anti-apoptotic factors, others (p53), of
apoptotic ones. In the mitochondrial environment their precise
role is now beginning to be unraveled. Some bind to mito-
chondrial DNA sequences similar to cognate nuclear nucleotide
sequences, and affect the mitochondrial transcription process,
mostly attenuating mitochondrial gene expression, in contrast to
their stimulatory effects on nuclear gene transcription. The
precise mechanism of action of these transcription factors on
mitochondrial gene expression, in relation to the apoptotic
process, is a major field of further research. The detailed me-
chanism of the mitochondrial action of these transcription
factors in the coordination of nuclear and mitochondrial apop-
totic events is an expanding research field.
The catalogue of nuclear transcription factors detected in
mitochondria is rapidly increasing. It is well known, that these
factors show multiple interactions in their nuclear and cyto-
plasmic environment [126]. These interactions modify their
DNA binding properties and their effects on transcription,
thus increasing their regulatory possibilities on gene tran-
scription. This could also be true as regards the mitochondrially
localized transcription factors and their effects on mitochondrial
transcription.In this review, the emphasis was placed on the genomic
actions of nuclear receptors and transcription factors in nuclei
and in mitochondria, relative to OXPHOS gene expression and
apoptosis. As already stressed, nuclear receptors and transcrip-
tion factors also exert non-genomic, rapid effects and certainly
such actions in mitochondria are important and could act in
accord with the genomic role of these regulatory proteins.
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